Brief: Sagimet Biosciences Announces Successful Completion Of End-Of-Phase 2 Interactions With FDA On The Development Of Denifanstat For Mash Phase 3 Program Initiation Expected By End Of 2024
29/10/2024 11:16
Oct 29 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES ANNOUNCES SUCCESSFUL COMPLETION OF
END-OF-PHASE 2 INTERACTIONS WITH FDA ON THE DEVELOPMENT OF
DENIFANSTAT FOR MASH; PHASE 3 PROGRAM INITIATION EXPECTED BY END
OF 2024
Source text: ID:nGNX2KRBlT
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage